153 related articles for article (PubMed ID: 30887881)
1. Expedited pharma patenting in Brazil.
Moreira P
Pharm Pat Anal; 2019 Mar; 8(2):51-59. PubMed ID: 30887881
[TBL] [Abstract][Full Text] [Related]
2. Update on Brazil's pharma patent landscape.
Gosain R
Pharm Pat Anal; 2016 Sep; 5(6):385-390. PubMed ID: 27804784
[TBL] [Abstract][Full Text] [Related]
3. The consequences of 'double examination' for pharmaceutical patent applications in Brazil.
Salerno G
Pharm Pat Anal; 2017 Mar; 6(2):49-51. PubMed ID: 28274178
[No Abstract] [Full Text] [Related]
4. Reaching a milestone in pharmaceutical patenting in Brazil.
Blasi GD
Pharm Pat Anal; 2018 Nov; 7(6):229-233. PubMed ID: 30632452
[No Abstract] [Full Text] [Related]
5. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].
Jannuzzi AH; Vasconcellos AG; de Souza CG
Cad Saude Publica; 2008 Jun; 24(6):1205-18. PubMed ID: 18545747
[TBL] [Abstract][Full Text] [Related]
6. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
Mueller LL; Taketsuma Costa SM
Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
[TBL] [Abstract][Full Text] [Related]
7. Patenting pharmaceuticals in China.
Han W; Luo J
Pharm Pat Anal; 2016 Jul; 5(4):249-59. PubMed ID: 27338759
[TBL] [Abstract][Full Text] [Related]
8. Patent reform in the US: what's at stake for pharmaceutical innovation?
Yancey A; Stewart CN
Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical patent term extension and patent prosecution in Brazil (1997-2018).
Mercadante E; Paranhos J
Cad Saude Publica; 2022; 38(1):e00043021. PubMed ID: 35107507
[TBL] [Abstract][Full Text] [Related]
10. [How much does the backlog on drug patents cost for health in Brazil?].
Jannuzzi AHL; Vasconcellos AG
Cad Saude Publica; 2017 Aug; 33(8):e00206516. PubMed ID: 28832788
[TBL] [Abstract][Full Text] [Related]
11. What are the risks of second medical use and dosing regimens in pharmaceutical patenting?
Kanz C; Gerhardt F
Pharm Pat Anal; 2014 Sep; 3(5):481-4. PubMed ID: 25374316
[No Abstract] [Full Text] [Related]
12. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
Miller CP; Ullrich JW
Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
[TBL] [Abstract][Full Text] [Related]
13. Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act.
Genieser LH; McCann CE
Pharm Pat Anal; 2012 Sep; 1(4):415-26. PubMed ID: 24236880
[TBL] [Abstract][Full Text] [Related]
14. Indian pharmaceutical patent prosecution: The changing role of Section 3(d).
Sampat BN; Shadlen KC
PLoS One; 2018; 13(4):e0194714. PubMed ID: 29608604
[TBL] [Abstract][Full Text] [Related]
15. Patent protection in Europe of pharmaceuticals found to have a further medical indication.
Cockbain J
Pharm Pat Anal; 2012 Mar; 1(1):17-8. PubMed ID: 24236708
[No Abstract] [Full Text] [Related]
16. Patent watch: Progress in three key patent disputes in 2009.
Nat Rev Drug Discov; 2010 Jan; 9(1):12-3. PubMed ID: 20050395
[No Abstract] [Full Text] [Related]
17. Patent protection versus public health.
Lancet; 2001 Nov; 358(9293):1563. PubMed ID: 11716874
[No Abstract] [Full Text] [Related]
18. Enforcing pharmaceutical and biotech patent rights in China.
Zhang YP; Deng MM
Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
[No Abstract] [Full Text] [Related]
19. Patent watch.
Harrison C
Nat Rev Drug Discov; 2012 Jan; 11(1):12-3. PubMed ID: 22212669
[No Abstract] [Full Text] [Related]
20. Proposed trade agreement could increase patent protection for pharmaceuticals.
Eggertson L
CMAJ; 2013 Jul; 185(10):E459-60. PubMed ID: 23695601
[No Abstract] [Full Text] [Related]
[Next] [New Search]
